TERRAMYCIN W/ POLYMYXIN B SULFATE
LOE Approachingoxytetracycline hydrochloride; polymyxin b sulfate
NDAOPHTHALMICOINTMENT
Approved
Jul 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Terramycin with Polymyxin B Sulfate is a fixed-dose combination ophthalmic ointment containing oxytetracycline hydrochloride (a tetracycline antibiotic) and polymyxin B sulfate (a polypeptide antibiotic) for topical eye infections. The combination provides broad-spectrum antimicrobial coverage against bacterial pathogens affecting the ocular surface. It is indicated for superficial ocular infections caused by susceptible organisms.
LOE Approaching
This mature, legacy ophthalmic antibiotic faces declining market relevance as newer agents and formulations emerge, likely supporting a smaller, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Terramycin W/ Polymyxin B offers limited long-term career growth due to approaching LOE and minimal linked job openings; roles emphasize cost management, market defense, and operational excellence rather than innovation. This product is best suited for early-career professionals seeking ophthalmic/specialty pharma experience or those transitioning to sunset product management.
Regional Sales Manager
Worked on TERRAMYCIN W/ POLYMYXIN B SULFATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.